Access our full analysis report here, it\u2019s free<\/a>.<\/p>\nWhat Is The Market Telling Us <\/p>\n
Illumina\u2019s shares are somewhat volatile and have had 14 moves greater than 5% over the last year. In that context, today\u2019s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. <\/p>\n
The previous big move we wrote about was 6 days ago when the stock gained 6.6% on the news that it appointed a high-profile Eli Lilly executive to its board and a price target increase from Barclays. Illumina appointed Daniel M. Skovronsky, the Chief Scientific and Product Officer of Eli Lilly, to its board of directors.\u00a0<\/p>\n
The move was viewed positively, as his expertise is expected to help the company’s innovation and business development efforts. Separately, Barclays analyst Luke Sergott raised the firm’s price target on Illumina to $145 from $122. While the analyst kept an Underweight rating on the shares, the note mentioned that life science and diagnostic tools are \u201cgaining favor among healthcare subsectors,\u201d and the firm expects in-line to modest beats in quarterly results for the group.<\/p>\n
Illumina is up 32.1% since the beginning of the year, and at $177.45 per share, it has set a new 52-week high. Despite the year-to-date gain, investors who bought $1,000 worth of Illumina\u2019s shares 5 years ago would now be looking at only $374.99.<\/p>\n
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you\u2019re unstoppable.<\/p>\n
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"What Happened? Shares of genomics company Illumina (NASDAQ:ILMN) fell 1.9% in the afternoon session after Swiss drugmaker Roche…\n","protected":false},"author":2,"featured_media":94911,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[278,134,18339,38668],"class_list":["post-94910","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-financial-analysis","tag-roche","tag-stock-market-news","tag-undefined-why-it-moves-single"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116841181659645561","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/94910","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=94910"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/94910\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/94911"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=94910"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=94910"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=94910"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}